Drug Development Pipeline for Metabolic Disease Research:
- AI-powered zebrafish in-vivo analysis is being utilized to expedite the identification of drug candidates in drug discovery.
- Based on automated lab facilities, ZEFIT allows high-throughput screening (HTS) to improve efficiency and precision in compound selection.
- The integration of Zebrafish models enables the swift and cost-effective in vivo testing of metabolic disease treatments.
- The use of big data analytics will favor the identification of potential therapeutic targets within a year.
- The company is continually enhancing and sophisticating its drug development pipelines through strategic partnerships with top pharmaceutical companies.
- ZEFIT’s service aims to streamline lead compound optimization and safety assessment, thereby advancing promising candidates to clinical trials.
- The company focuses on innovative treatments for metabolic diseases like diabetes, obesity, and liver disorders, enhancing drug efficacy and stability through AI-based modelling and automated experimental infrastructure.
If you are looking for metabolic disease or anticancer drug discovery platforms, you can find them at ZEFIT.
Click here if you are interested in ZEFIT Services.
View More: Drug Development Pipeline for Metabolic Diseases